Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Psychiatry Consortium written with image of a brain

This is the first project to be funded by the international Psychiatry Consortium, a £4 million collaboration between seven global pharmaceutical companies, and two leading research charities, convened and managed by the Medicines Discovery Catapult, that supports high-value drug discovery projects in this area of unmet patient need.

The world-leading team of academic researchers will use their newly designed technical approach to assess which proteins are selectively produced by the kalirin gene in the human brain, and how this differs from other human tissues.

Once this is understood it may be possible to identify the proteins that represent the most promising drug targets for the potential treatment of schizophrenia, how they affect the function of cells, and begin to develop drugs to alter their function.

Liz Tunbridge, Associate Professor in the Department of Psychiatry at the University of Oxford, and lead investigator for the study, commented,

 
“We desperately need new treatments for schizophrenia because current drugs can cause side effects, do not work for everyone and do not improve all the symptoms. However, it has been difficult to improve this situation because of our limited understanding of the changes in the brain that underlie schizophrenia. This exciting collaboration will enable us to start the long journey from genetic research to the development of new drugs. Ultimately, we hope that our research will one day lead to new medicines that improve the lives of people with schizophrenia.”

Dr. Hugh Marston, Head of Department CNS Diseases Research at Boehringer Ingelheim, said,

“Schizophrenia is a serious mental health condition that alters a person’s perception of reality, impacts how they think, feel, and behave. Current treatment options leave significant room for improvement through the development of new therapeutics. We recognize the importance of finding new solutions for people living with neuropsychiatric disorders with our innovative CNS research program as a key focus area at Boehringer Ingelheim. As this program focuses on improving our understanding of the mechanisms that underly these complex disorders, we are pleased to be part of this first research project of the Psychiatry Consortium. We hope a successful completion will make a real impact on the development of innovative treatment options.”

Diana Gallagher, Head of External Innovation, Biogen, said, 

“At Biogen we recognise the enormous impact psychiatric disorders have on mental health. The significant gap in treatment options leaves many with poor long-term quality of life and disability. Being part of the Medicines Discovery Catapult (MDC) Psychiatry Consortium, builds on Biogen’s recent licensing and partnership of later-stage drug candidates for psychiatry, and participation in this project, and its successful outcome, could inform our thinking on neuropsychiatric disorders where Biogen will aim to develop new treatments for patients.”

Professor Chris Molloy, Chief Executive Officer at Medicines Discovery Catapult (MDC), said, 

“At a time when mental health research is gravely underfunded, this group of academic and industrial scientists, brought together in the Psychiatry Consortium by Medicines Discovery Catapult, is delivering improved understanding of schizophrenia in ways that can be directly applied to new drug discovery.

“This is a landmark for the Psychiatry Consortium – one of many to follow - intended to yield tangible improvements for those living with schizophrenia.”

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Helping People with Psychosis Feel Less Distressed May Help Reduce the Risk of Self-harm

New research shows that by lessening the severity and impact of persecutory symptoms of psychosis, it may be possible to reduce the likelihood of someone with psychosis having thoughts of suicide or harming themselves.

Ground-breaking Treatment Offers New Hope for Patients with Persecutory Delusions

Feeling Safe is a new treatment programme for persecutory delusions, which promises a step change in the treatment of severe mental health problems.

Depressive Symptoms and Risky Behaviours Among Adolescents in Low-and Middle-Income Countries

New meta-analysis, published in the Journal of the American Academy of Child & Adolescent Psychiatry, shows adolescents with depressive symptoms were more likely to engage in risky behaviours compared with non-depressed adolescents.

Adolescent Mental Health and Development in the Digital World

A new project has been awarded funding from the UKRI £24 million investment into improving the mental health and wellbeing of adolescents in the UK.

£24m Investment into Adolescent Mental Health to Enable Young People to Flourish

UKRI have announced a major £24 million investment into improving the mental health and wellbeing of adolescents in the UK. One of the projects being funded is led by Professor Kam Bhui in the Department of Psychiatry, it will bring together diverse creative-arts, digital and health experts to investigate how adverse childhood experiences (ACEs) can affect adolescents' mental health.

£36 Million Boost for AI Technologies to Revolutionise NHS Care

An Oxford project using artificial intelligence to develop digital triage tools for mental health clinicians (CHRONOS) is one of 38 projects supported by the second wave of the NHS AI Lab's AI in Health and Care Award.